Invicta Medical
Operates as a medical technology company that develops therapies for sleep apnea.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
Established in 2012, Invicta Medical, which has been rebranded as Restera, is a clinical-stage medical technology firm positioned to address the significant market for sleep apnea therapies. The company was founded by Steven Kent and Hal Kent. Rick O'Connor currently serves as the CEO.
The company is focused on developing treatments for obstructive sleep apnea (OSA), a condition affecting an estimated one billion people worldwide, with a significant number remaining undiagnosed. The economic burden of untreated sleep apnea in the United States alone is estimated at $150 billion annually due to associated health conditions and loss of productivity. Restera targets the shortcomings of existing therapies, such as CPAP machines, which suffer from low patient compliance rates due to their cumbersome and intrusive nature.
Restera's primary offering is an intelligent neurostimulation system, which is described as the world's first and only injectable sleep apnea therapy. This system involves a minimally invasive procedure, taking approximately five to ten minutes, where a small, flexible device is injected near the hypoglossal nerve without scalpels or surgery. The implant stimulates the genioglossus muscle, moving the tongue forward to keep the airway open during sleep. The platform includes options for a traditional implantable power source or a wireless, fully injectable device without an onboard battery. This approach allows for the treatment of a broad range of patients, including those with a high BMI or different types of airway collapse.
The company has a strong intellectual property portfolio with 35 patents and patents pending. Clinical data from six studies involving 65 patients has demonstrated a significant reduction in the Apnea-Hypopnea Index (AHI) on the first night of therapy, a notable improvement over existing treatments. To date, Invicta Medical has raised a total of $73.3 million over five funding rounds, with the latest being a Series C round of $25 million in April 2023. The company is seeking further funding to complete feasibility studies and aim for a commercial launch.
Keywords: neurostimulation, sleep apnea, obstructive sleep apnea, medical device, injectable therapy, hypoglossal nerve stimulation, minimally invasive, clinical-stage, ENT, airway management